Were you unable to attend Transform 2022? Check out all of the summit sessions in our on-demand library now! Watch here.


InnerPulse, a North Carolina company developing treatments for abnormal heart rhythms, said it has raised $50 million in new equity financing.

The syndicate of investors included Johnson & Johnson Development Corporation, Medtronic, Inc., Synergy Life Science Partners, Ascent Biomedical Ventures, Delphi Ventures and Frazier Heathcare Ventures. Additonally, Boston Scientific and Greatbatch, Inc. remain significant stockholders of InnerPulse, the company said.

From the statement:

The Company’s products employ an innovative technology to simplify the implant utilizing a minimally invasive approach that shortens the procedure, reduces post implant discomforts, and renders the device invisible. The minimally invasive nature of the technology will expand the number of implanting physicians, thereby providing access to more patients who critically need defibrillator technology.

VentureBeat's mission is to be a digital town square for technical decision-makers to gain knowledge about transformative enterprise technology and transact. Discover our Briefings.